Skip to Content
Merck
CN
  • Exosome-sheathed ROS-responsive nanogel to improve targeted therapy in perimenopausal depression.

Exosome-sheathed ROS-responsive nanogel to improve targeted therapy in perimenopausal depression.

Journal of nanobiotechnology (2023-08-09)
Yue Hu, Min Zhao, Hui Wang, Yang Guo, Xiaolan Cheng, Tong Zhao, Hanqing Wang, Yafeng Zhang, Yong Ma, Weiwei Tao
ABSTRACT

The development of natural membranes as coatings for nanoparticles to traverse the blood-brain barrier (BBB) presents an effective approach for treating central nervous system (CNS) disorders. In this study, we have designed a nanogel loaded with PACAP and estrogen (E2), sheathed with exosomes and responsive to reactive oxygen species (ROS), denoted as HA NGs@exosomes. The objective of this novel design is to serve as a potent drug carrier for the targeted treatment of perimenopausal depression. The efficient cellular uptake and BBB penetration of HA NGs@exosomes has been demonstrated in vitro and in vivo. Following intranasal intervention with HA NGs@exosomes, ovariectomized mice under chronic unpredictable mild stress (CUMS) have shown improved behavioral performance, indicating that HA NGs@exosomes produced a rapid-onset antidepressant effect. Moreover, HA NGs@exosomes exhibit notable antioxidant and anti-inflammatory properties and may regulate the expression of pivotal proteins in the PACAP/PAC1 pathway to promote synaptic plasticity. Our results serve as a proof-of-concept for the utility of exosome-sheathed ROS-responsive nanogel as a promising drug carrier for the treatment of perimenopausal depression.